Literature DB >> 26537785

Preliminary Characterization of a Leptin Receptor Knockout Rat Created by CRISPR/Cas9 System.

Dan Bao1, Yuanwu Ma1, Xu Zhang1, Feifei Guan1, Wei Chen1, Kai Gao1, Chuan Qin2, Lianfeng Zhang1.   

Abstract

Leptin receptor, which is encoded by the diabetes (db) gene and is highly expressed in the choroid plexus, regulatesenergy homeostasis, the balance between food intake and energy expenditure, fertility and bone mass. Here, using CRISPR/Cas9 technology, we created the leptin receptor knockout rat. Homozygous leptin receptor null rats are characterized by obesity, hyperphagia, hyperglycemia, glucose intolerance, hyperinsulinemia and dyslipidemia. Due to long-term poor glycemic control, the leptin receptor knockout rats also develop some diabetic complications such as pancreatic, hepatic and renal lesions. In addition, the leptin receptor knockout rats show a significant decrease in bone volume and bone mineral density of the femur compared with their wild-type littermates. Our model has rescued some deficiency of the existing rodent models, such as the transient hyperglycemia of db/db mice in the C57BL/6J genetic background and the delayed onset of glucose intolerance in the Zucker rats, and it is proven to be a useful animal model for biomedical and pharmacological research on obesity and diabetes.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26537785      PMCID: PMC4633582          DOI: 10.1038/srep15942

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


Leptin receptor (Lepr), which is encoded by the diabetes (db) gene and is highly expressed in the choroid plexus, regulates energy homeostasis, the balance between food intake and energy expenditure, fertility and bone mass, by binding to leptin, which is encoded by the obese (ob) gene1234. Mapping of the gene’s chromosomal locations in rodents revealed that mutations in Lepr were the basis for obesity/diabetes in rodents and humans4. Accordingly, Lepr-deficientmice, the autosomal recessive diabetes mutants (db/db), have severe early-onset obesity, extreme insulin resistance and develop diabetes567, which have been used in studies on obesity and diabetes. The rat equivalent of the db/db mouse is the Zucker rat, also known as the fa/fa rat8, which carries a spontaneous autosomal mutation in the Lepr gene and develops a similar phenotype of hyperphagia leading to morbid obesity910, glucose intolerance and insulin resistance51112. Although the Zucker rats have often been used to study type 2 diabetes-like syndromes, they do not develop the full phenotype of type 2 diabetes. For example, the Zucker rats do not present with a typical high blood glucose level10. The Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated (Cas) system is a RNA-based adaptive immune system in bacteria and archaea and now has been engineered as RNA-guided endonucleases for genome editing. A type II CRISPR system functions by the CRISPR RNA (crRNA) interacting with a trans-activating crRNA (tracrRNA) to form a crRNA-tracrRNA duplex which could be replaced with a single guide RNA (gRNA), then leading to the formation of Cas9 protein-containing ribonucleoprotein complexes that recognized and cleave a target DNA sequence1314. Unlike other engineered nucleases, such as zinc finger nucleases and transcription activator-like effector nucleases, the CRISPR/Cas9 system does not require the engineering of specific protein pairs for each target site, which has made the CRISPR/Cas9 system develop into convenient genome editing tool for producing gene knockout models of many species1516171819. Here, we generated the Lepr knockout rats using the CRISPR/Cas9 system. The Lepr knockout rats were obese, sterile, and diabetic and had decreased bone mineral density, which would expand the suite of animal models for biomedical and pharmacological research on obesity and type 2 diabetes.

Results

Generation of leptin receptor knockout rat using CRISPR/Cas9 system

Two gRNAs targeting Lepr exon 4 were transcribed in vitro. A mixture of Cas9 mRNA (20 ng/ul) and gRNA (10 ng/ul per gRNA) were microinjected into the cytoplasm of zygotes of Sprague Dawley (SD) rats. A total of 60 injected zygotes were transferred to 2 pseudopregnant female SD rats, and 8 pups were born. The PCR amplification of the targeting loci showed that four rats (founder 2, 4, 5 and 7) had Lepr deletion (Fig. 1A). Further sequencing confirmed that six rats (founder 2–7) had a frame shift mutation (Fig. 1B). Founder 2 was chosen to establish a colony (designated as Lepr−/−), which carried a 298-bp deletion from No. 90043 bp to 90341 bp in the Lepr genome DNA sequence (NC_005104.4) and a 4-bp insertion, and resulted in a termination codon TGA, deleting 997- amino acid of LEPR. Western blot analysis of total protein from liver tissue of the Lepr−/− rats confirmed the absence of LEPR (Fig. 1C).
Figure 1

Generation of Leptin receptor knockout rat using CRISPR/Cas9 system.

(A) Target loci of Lepr were amplified using genomic DNA templates from founders. M: DNA molecular weight marker DL2000; WT: Template DNA was replaced with wild-type genomic DNA; 1-8: Founder rats generated by microinjection. (B) PCR products of the targeted fragment in the Lepr in rats were sequenced. The protospacer adjacent motif (PAM) sequence was underlined and highlighted in green; the targeting sites were red; the insertions were purple, lower case; insertions (+) or deletions (−) were shown to the right of each allele. The E3, E4 and E5 represents exon 3, exon 4 and exon 5 of Lepr respectively. (C) Protein level of LEPR in the liver tissues of WT littermates and Lepr−/− rats were detected by western blot, using β-actin as normalization.

Leptin receptor knockout induced obesity and hyperphagia

The body weight was measured from 1 to 8 months of age. The male Lepr−/− rats emerged with severe early-onset obesity as early as 1 month of age and were approximately 60% heavier at 8 months of age compared with their wild-type (WT) littermates (Fig. 2A,B, n = 12, P = 0.002). The female Lepr−/− rats presented more severe obesity than male rats and were approximately160% heavier at 8 months of age (Fig. 2C, n = 15, P = 0.02). The increased body weight of Lepr−/− rats was associated with significantly elevated daily food consumption in both genders (Fig. 2D,E).
Figure 2

Body weight and daily food intake measurement of Leptin receptor knockout rat.

(A) A picture of a WT littermate and a Lepr−/− rat at 8 months of age. (B,C) Body weight was measured over 8 month for male WT littermate (n = 19), male Lepr−/− rat (n = 12), female WT littermate (n = 13) and female Lepr−/− rat (n = 15). (D,E) Daily food intake was measured over 8 month for male WT littermate (n = 12), male Lepr−/− rat (n = 8), female WT littermate (n = 8) and female Lepr−/− rat (n = 8).*P < 0.05, **P < 0.01, ***P < 0.001 versus WT littermate rats.

Leptin receptor knockoutinduced hyperglycemia, glucose intolerance andhyperinsulinemia

Fasting and random glucose levels were measured from 1 to 8 months of age in both genders. The male Lepr−/− rats emerged with higher fasting glucose level at 4 months of age and this hyperglycemia continued to 8 months of age (Fig. 3A). Significantly higher random glucose levels occurred as early as 2 months of age in male Lepr−/− rats and reached peak glucose at 4 months of age, which increased 1.64-fold compared with those of their WT littermates (Fig. 3C, n = 12, P = 0.02). Random hyperglycemia also continued to 8 months of age. However, persistent hyperglycemia was not observed in the female Lepr−/− rats (Fig. 3B,D).
Figure 3

Blood glucose, glucose intolerance and serum insulin test of Leptin receptor knockout rat.

(A–D) Fasting and random blood glucose were measured over 8 month for male WT littermate (n = 19), male Lepr−/− rat (n = 12), female WT littermate (n = 13) and female Lepr−/− rat (n = 15). (E,F) 2, 4 and 8months of age WT littermate and Lepr−/− rat (n = 8 for each group) in both genders were administrated with D-glucose, and serum glucose levels were determined at 0, 30, 60, 90 and 120 min after administration. (G,H) Serum insulin levels of WT littermate and Lepr−/− rat (n = 4 for each group) in both genders were measured in glucose tolerance tests meanwhile. *P < 0.05, **P < 0.01, ***P < 0.001 versus WT littermates in Figure 3A-3D; # refers to differences between WT-2M and Lepr−/−-2M; & refers to differences between WT-4M and Lepr−/−-4M and * refers to differences between WT-8M and Lepr−/−-8M in Fig. 3E–H; #, & and *P < 0.05, ##, && and **P < 0.01, ###, &&& and ***P < 0.001.

According to the above-described glucose levels, we chose 2-, 4- and 8-month old rats on which to performa glucose tolerance test. After the glucose loading, the Lepr−/− rats showed rapid and remarkable elevation of serum glucose levels, whereas serum glucose elevation was relatively slow and brief in their WT littermates. Glucose intolerance appeared in maleLepr−/− rats at 2 months of age and deteriorated with aging. In particular, at 8 months of age the peak glucose level reached 22.2 mmol/L and the glucose level was sustained at 16.3 mmol/L at 120 min after glucose loading (Fig. 3E, n = 8, P = 0.002). In female Lepr−/− rats, glucose intolerance only was observed at 4 months of age (Fig. 3F). To further evaluate glucose homeostasis in Lepr−/− rats, serum insulin level were measured in a glucose tolerance test. The Lepr−/− rats showed significant hyperinsulinemia at baseline and presented a dramatic increase in serum insulin levels at 2, 4 and 8 months of age in both genders after the glucose loading (Fig. 3G,H).

Leptin receptor knockout induced dyslipidemia

Diabetes-associated lipid metabolism parameters were measured at 2, 4 and 8 months of age in both genders. The Lepr−/− rats showed similar lipid metabolism characteristics in both genders, so we merged the parameters of males and females (Table 1). Circulating triglycerides, total cholesterol and high density lipoprotein were all significantly increased in Lepr−/− rats compared with those of their WT littermates at 2, 4 and 8 months of age. A diabetic condition only altered the low density lipoprotein in 8-month old Lepr−/− rats significantly. Dyslipidemia appeared in Lepr−/− rats at 2 months of age and deteriorated with aging.
Table 1

Fasting serum biochemistry at 2, 4 and 8 months of age.

Group2M
4M
8M
WTLepr−/−WTLepr−/−WTLepr−/−
Number1168977
CHO (mM)1.56 ± 0.732.46 ± 0.56 *1.69 ± 0.765.89 ± 1.04 ***1.94 ± 0.768.15 ± 2.70 ***
TG (mM)0.81 ± 0.392.84 ± 0.90 ***1.16 ± 0.555.00 ± 2.08 ***1.20 ± 0.786.26 ± 3.08 **
HDL (mM)1.11 ± 0.551.78 ± 0.63 *0.91 ± 0.493.73 ± 0.95 ***1.44 ± 0.635.89 ± 2.28 ***
LDL (mM)0.21 ± 0.100.32 ± 0.220.23 ± 0.120.29 ± 0.070.21 ± 0.050.76 ± 0.27 ***

CHO, total cholesterol; TG, triglycerides; HDL, high density lipoprotein; LDL, low density lipoprotein.

*P < 0.05, **P < 0.01, *** P < 0.001 versus WT littermate.

Leptin receptor knockout induced pathological changes of pancreas, liver, adipose tissue and kidney

The Lepr−/− ratsand their WT littermates were chosen for observation of the pathological changes induced by Lepr knockout at 8 months of age. Compared with their WT littermates, the pancreatic islets of the Lepr−/− rats exhibited obviously severe vacuolation, hypertrophy, fibrosis and hemorrhage, and had irregular boundaries (Fig. 4A). Infiltration of inflammatory cells was also observed in the islet (see Supplementary Fig. S3D). Severe hepatic steatosis, characterized by the accumulation of higher levels of lipid in the hepatic intracellular vesicles, was evident in the Lepr−/− rats (Fig. 4B). The adipocytes of the Lepr−/− rats were obviously larger (Fig. 4C). The kidney tissues of the Lepr−/− rats exhibited expansion of glomerular matrix, segmental glomerulosclerosis and tubular damage such as tubular expansion and regeneration (Fig. 4D).
Figure 4

Pathological changes of pancreas, liver, adipose tissue and kidney in Leptin receptor knockout rat.

(A–C) Haematoxylin and eosin (H&E) staining of the pancreas, liver and adipose tissue in WT littermates and theLepr−/− rats (magnification × 100); (D) H&E staining of the kidney in WT littermates and the Lepr−/− rats (magnification × 200). ☆presents pancreas fibrosis, black arrows presents pancreas hemorrhage, △presents renal tubular damage.

Leptin receptor knockout induced the decrease of bone volume and bone mineral density

WT littermates and Lepr−/−rats were euthanized (n = 4 for each group) at 8 months of age. Their femurs were dissected and the distal femur were analyzed by μCT. The trabecular bone of the distal femur was significantly decreased in the Lepr−/− rats compared with that of WT littermates at 8 months of age (Fig. 5A). The 3-D analysis indicated that the bone volume/total (tissue) volume (BV/TV) of the Lepr−/− rats was decreased by 26.40% (Fig. 5B, P = 0.006), and the trabecular number (Tb.N) was decreased by 23.08% (Fig. 5C, P = 0.03), whereas trabecular separation (Tb.Sp) was increased by 53.73% (Fig. 5E, P = 0.02). The bone mineral density (BMD) of the distal femur was significantly decreased by 29.35% in the Lepr−/− rats compared with their WT littermates (Fig. 5F, P = 0.02).
Figure 5

Bone volume and equivalent density analysis of Leptin receptor knockout rat.

(A) μCT images of the trabecular bone compartment in the distal femur of the WT littermate and Lepr−/− rats at 8 months of age (Scale bar: 1 mm). (B–F) Bone volume/total (tissue) volume (BV/TV), trabecular number (Tb.N), trabecular thickness (Tb.Th), trabecular separation (Tb.Sp) and bone mineral density (BMD) were measured in the WT littermates and Lepr−/− rats at 8 months of age (n = 4 for each group, *P < 0.05, **P < 0.01 versus WT littermates; NS: no significant difference).

Discussion

In the past few decades, obesity and obesity-related disease, such as type 2 diabetes, have been shown to be directly related to increased mortality and reduced life expectancy20. Human type 2 diabetes is a complex heterogeneous disease; it is clinically characterized by obesity, overt hyperglycemia, dyslipidemia and glucose intolerance21. Moreover, long-term poor glycemic control in diabetic patients leads to the development of microvascular and macrovascular complications2223. Patients with type 2 diabetes also present with a higher potential for falls and risk for fracture than nondiabetic individuals2425. Various animal models of type 2 diabetes have been established to study human type 2 diabetes. However,these models do not develop the full phenotype of type 2 diabetes. Thus, another animal model, in particular a rat model, due to its physiology advantages compared with mice, should be helpful for Lepr’s clinical applications. Here, we created theLepr knockout rats (named as Leprtm1Ilas in our laboratory Rat Resource website: http://123.1.153.158/portal/root/website_yky) using CRISPR/Cas9 technology.The phenotypes of thedb/db mice, the Zucker rats and theLepr−/− rats was summarized in Table 2. Our two gRNAs targeting the fourth exon of the Lepr gene, induced a 298-bp deletion and a 4-bp insertion and resulted TGA termination codon prematurely, which led to the absence of LEPR in the Lepr−/− rats. However, the Zucker rat model had a spontaneous missense mutation in the Lepr gene, which does not affect the expression level of LEPR26. The differences in LEPR expression resulted in disparate phenotypes between our Lepr−/− rats and the Zucker rats. The Lepr−/− rats are obese and develop mild random hyperglycemia, hyperinsulinemia and dyslipidemia as early as 8 weeks of age. Whereas, the Zucker rats do not present with typical high blood glucose levels10, and they develop glucose intolerance and insulin resistance within 12 weeks of age in a mixed genetic background (a cross between Merck 3M and Sherman rats)27, and demonstrate a delayed onset of glucose intolerance to 21–23 weeks when bred into the SD background28. Consistent with the Zucker rats, our Lepr−/− rats demonstrated a significant decrease in BV/TV compared with their WT littermates29. Leptin has been found to restrain corticotropic releasing hormone and to stimulate gonadotropin releasing hormone release from the hypothalamus30. Leptin-deficiency or Lepr-deficiency obese animals are both hypercortisolic and hypogonadal3. Increased corticosteroid production and decreased estrogen presence favor an increase in osteoclast number and subsequent increase in bone resorption, which may predominate in the Lepr−/− rats to increase the bone loss.
Table 2

Comparison of the phenotypes among db/db mice, the Zucker rats and our Lepr −/− rats.

 db/db miceZucker ratsLepr−/−rats
Lepr disruptionMutation at exon 19 g→t3536 resulted in the deletion of the intracellular domain of Lepr.Mutation at A880→C resulted in the replacement of Gln269→Pro37, which does not affect the expression level of LEPR26.Lepr exon 4, 298-bp deletion and 4-bp insertion, generated stop codon, and leads the absence of LEPR expression.
ObesityAppears at 1 month of ageAppears at 1 month of ageAppears at 1 month of age
HyperphagiaYesYesYes
HyperglycemiaC57BL/6J background present with transient hyperglycemia; C57BL/KSJ background exhibit hyperglycemia, only survive to 10 months of age32.Normal blood glucose levels10.Mild hyperglycemia during 8 months of age.
Glucose intoleranceYesYes, delayed onset of glucose intolerance28.Yes, appears as early as 2 months of age.
Diabetic complicationRenal lesion;38 increased bone formation3.Renal lesion; decreased bone volume29.Pancreas, liver and renal lesion; decreased bone volume.
Another commonly used animal model of type 2 diabetes is db/db mice, which are characterized by hyperphagia, morbid obesity and extreme insulin resistance531. The hyperglycemia of db/db mice depends on the background strain. For example, db/dbmice present with transient hyperglycemia in a C57BL/6J genetic background; although db/db mice in C57BL/KSJ genetic background exhibit uncontrollable hyperglycemia, they could only survive to 10 months of age32. Our Lepr−/− rat presents with mild hyperglycemia as early as 1 month of age and this higher levels continued to 8 months of age. The chronic hyperglycemia of the Lepr−/− rat demonstrates the advantage of long-term observation on the development of diabetes and diabetes-related complications. The db/db mice and the Lepr−/− rat can possible complement each other in research on the development of diabetes. In conclusion, our initial characterization shows that knockout of the Lepr gene in SD rats leads to severe obesity, hyperphagia, glucose intolerance, hyperinsulinemia, dyslipidemia, decreased bone mineral density and partial diabetes complications. Our model compensates for some deficiencies of the existing rodent models, especially with respect to chronic hyperglycemia, and it is proven to be a usefulanimal model for obesity and diabetes research.

Methods

The use of animals and all experimental protocol were approved by the Animal Care and Use Committees of  The Institute of Laboratory Animal Science of Peking Union Medical College (ILAS-GC-2010-044), including the establishment of the Leprknockout rats, fasting and random glucose test, glucose tolerance test, serum insulin level test, serum biochemistry test, histological analysis and microcomputedtomography analysis. And all the methods were carried out in accordance with the approved guidelines mentioned above.

Animals

The Lepr knockout rats were generated by CRISPR/Cas9 as described previously33. In brief, we designed two pairs ofsynthesized oligonucleotides for gRNA targeting on the exon 4 of Lepr, TAGGCAAATCATCTATAACTTC and AAACGAAGTTATAGATGATTTG; TAGGCTGAAAGCTGTCTTTCAG and AAACCTGAAAGACAGCTTTCAG, which were annealed and cloned into the pUC57-gRNA expression vector (Plasmid #51132, Addgene, Cambridge, MA, USA, obtained from Professor Xingxu Huang). The gRNA expression plasmids were linearized with Dra I and used as templates for in vitro transcription using the MEGAshortscript Kit (Ambion, AM1354). The Cas9 expression plasmid (Plasmid #44758, Addgene, Cambridge, MA, USA, obtained from Professor Xingxu Huang) was linearized with Age I and used as the template for in vitro transcription using the T7 Ultra Kit (Ambion, AM1345). Transcribed Cas9 mRNA and gRNA were both purified by using the MEGAclear Kit (Ambion, AM1908), and then a mixture of transcribed Cas9 mRNA and gRNA was microinjected into Sprague Dawley (SD) rat (purchased from Beijing Vital River Laboratories Animal Center which were introduced from Charles River) zygotes to generate the Lepr−/− rat. Microinjections were performed in the cytoplasm of zygotes using a Nikon Microinjection system under standard conditions. The rat was genotyped by PCR with the primers, 5′ CTTGTGTCCAGAGCCTTCCTATAAC and 5′ ATTCCCCATGTTGTCTAGTAGTGATC. For genotyping, a 662-bp fragment of WT and a 368-bp fragment of the Lepr knockout gene were amplified with 30 PCR cycles consisting of94 °C for 30 s, 60 °C for 30 s and 72 °C for 45 s. All rats used in this study were maintained on a SD genetic background and were bred in an AAALAC-accredited facility. Rats were housed in a room kept at 23 ± 2 °C with a 12:12 h light/dark cycle and were provided with standard food and water libitum.The use of animals was approved by the Animal Care and Use Committees of The Institute of Laboratory Animal Science of Peking Union Medical College (ILAS-GC-2010-044).

Protein Extraction and Western Blot Analysis

The rats were euthanized and total protein lysates from the rat liver tissues were prepared as previously described34. After SDS-PAGE and transfer of the bands to nitrocellulose (Millipore), the membranes were incubated overnight with antibodies against LEPR (Santa Cruz, sc-8325). After incubation with the appropriate secondary antibody for 1h at room temperature, antibody binding was detected with an HRP-conjugated immunoglobulin G (Santa Cruz) using a chemiluminescence detection system (Santa Cruz). For quantitative analysis, the LEPR level was normalized to β-actin.

Body Weight and Food Consumption

WT littermates and Lepr−/− rats of both genders were weighed every month from 1 to 8 months of age. WT littermates and Lepr−/− rats were provided with standard food and water libitum. Food was weighed, and the average daily intake was calculated from 1 to 8 months of age.

Fasting and Random Blood Glucose

WT littermates and Lepr−/− rats of both genders were fasted overnight (14 h) but given water libitum. Blood was collected by tail vein puncture and blood glucose was analyzed by a One Touch Ultra glucometer (YZB/USA 6891). Random blood glucose measurement was performed at 9:00 a.m. over 8 month in both genders.

Glucose Tolerance Test and Serum Insulin Level

WT littermates and Lepr−/− rats of both genders were fasted overnight (14 h) but given water libitum. On the day of the test, the rats were weighed, and blood was collected by tail vein puncture. Blood glucose was analyzed by a One Touch Ultra glucometer (YZB/USA 6891). After a baseline glucose concentration was obtained, the rats were injected intraperitoneally with D-glucose at 1 g/kg body weight. Blood glucose levels were sampled from the tail at 30, 60, 90 and 120 min after injection. Meanwhile, 100 μl of blood was collected for serum insulin level test using rat/mouse insulin ELISA kits (Millipore).

Serum Biochemistry

WT littermates and Lepr−/− rats of both genders were fasted overnight (14 h) but given water libitum. Blood was collected by tail vein puncture. Whole blood was centrifuged at 3000 g for 10 min at 4 °C to obtain the serum and prepared for serum total cholesterol (CHO), triglycerides (TG), high density lipoprotein (HDL) and low density lipoprotein (LDL) detection using a HITACHI 7100 Automatic Analyzer.

Histological Analysis

For light microscopy, the rats were euthanized, and the pancreas, liver, kidney and abdominal adipose tissue were fixed in 4% formaldehyde and mounted in paraffin blocks. The sections were stained with haematoxylin and eosin (H&E) and analyzed using the Aperio Image Scope v8.2.5 software. The sections were analyzed by an observer blinded to the rat genotypes.

Microcomputed Tomography (μCT) Analysis

WT littermates and Lepr−/− rats 8 months of age were euthanizedand their femurs were dissected. Measurements of trabecular architecture were performed on the distal femur cleared of all soft tissue using Siemens INVEON LG CT. After an initial scout scan, a total of 100 slices with an increment of 10 μm were obtained on each bone sample, starting 1.0 mm below the growth plate. The area for analysis was outlined within the trabecular compartment, excluding the cortical and subcortical bone. Every 5 sections were outlined, and the intermediate sections wereinterpolated with the contouring algorithm to create a volume of interest. Segmentation values used for analysis were determined using Inveon Research Workplace. A three-dimensional (3-D) analysis was performed to determine BV/TV, trabecular number (Tb.N), trabecular thickness (Tb.Th) and trabecular separation (Tb.Sp). A two-dimensional (2-D) analysis was performed to determine bone mineral density (BMD). The mean cortical thickness (Ct.Th) was determined by distance measurements at 4 different points on the cortical slice.

Statistical Analysis

The data were analyzed by Two Independent-Samples non-parametric test. The data were expressed as the means ± SEMs from individual experiments. The differences were considered significant at P < 0.05.

Additional Information

How to cite this article: Bao, D. et al. Preliminary Characterization of a Leptin Receptor Knockout Rat Created by CRISPR/Cas9 System. Sci. Rep. 5, 15942; doi: 10.1038/srep15942 (2015).
  38 in total

Review 1.  Leptin, bone mass, and the thrifty phenotype.

Authors:  Mark W Hamrick
Journal:  J Bone Miner Res       Date:  2004-07-21       Impact factor: 6.741

Review 2.  Genome modification by CRISPR/Cas9.

Authors:  Yuanwu Ma; Lianfeng Zhang; Xingxu Huang
Journal:  FEBS J       Date:  2014-11-07       Impact factor: 5.542

Review 3.  Obese and diabetes: two mutant genes causing diabetes-obesity syndromes in mice.

Authors:  D L Coleman
Journal:  Diabetologia       Date:  1978-03       Impact factor: 10.122

Review 4.  Hypothalamic and genetic obesity in experimental animals: an autonomic and endocrine hypothesis.

Authors:  G A Bray; D A York
Journal:  Physiol Rev       Date:  1979-07       Impact factor: 37.312

5.  The influence of genetic background on the expression of the obese (Ob) gene in the mouse.

Authors:  D L Coleman; K P Hummel
Journal:  Diabetologia       Date:  1973-08       Impact factor: 10.122

6.  Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass.

Authors:  P Ducy; M Amling; S Takeda; M Priemel; A F Schilling; F T Beil; J Shen; C Vinson; J M Rueger; G Karsenty
Journal:  Cell       Date:  2000-01-21       Impact factor: 41.582

Review 7.  The Zucker-fatty rat: a review.

Authors:  G A Bray
Journal:  Fed Proc       Date:  1977-02

8.  Generation of eGFP and Cre knockin rats by CRISPR/Cas9.

Authors:  Yuanwu Ma; Jing Ma; Xu Zhang; Wei Chen; Lei Yu; Yingdong Lu; Lin Bai; Bin Shen; Xingxu Huang; Lianfeng Zhang
Journal:  FEBS J       Date:  2014-08-13       Impact factor: 5.542

9.  Characterization of bone structure in leptin receptor-deficient Zucker (fa/fa) rats.

Authors:  Joseph A Tamasi; Brian J Arey; Donald R Bertolini; Jean H M Feyen
Journal:  J Bone Miner Res       Date:  2003-09       Impact factor: 6.741

Review 10.  The BBZDR/Wor rat model for investigating the complications of type 2 diabetes mellitus.

Authors:  Rebecca S Tirabassi; Joan F Flanagan; Tiangen Wu; Edward H Kislauskis; Paul J Birckbichler; Dennis L Guberski
Journal:  ILAR J       Date:  2004
View more
  20 in total

Review 1.  CRISPR/Cas9, the Powerful New Genome-Editing Tool for Putative Therapeutics in Obesity.

Authors:  María José Franco-Tormo; Mireille Salas-Crisostomo; Nuno Barbosa Rocha; Henning Budde; Sérgio Machado; Eric Murillo-Rodríguez
Journal:  J Mol Neurosci       Date:  2018-05-07       Impact factor: 3.444

Review 2.  [Bone and adipose tissue formation].

Authors:  J Luther; J-P David
Journal:  Z Rheumatol       Date:  2016-09       Impact factor: 1.372

Review 3.  Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects.

Authors:  Hongyi Li; Yang Yang; Weiqi Hong; Mengyuan Huang; Min Wu; Xia Zhao
Journal:  Signal Transduct Target Ther       Date:  2020-01-03

4.  Large Yellow Tea Extract Ameliorates Metabolic Syndrome by Suppressing Lipogenesis through SIRT6/SREBP1 Pathway and Modulating Microbiota in Leptin Receptor Knockout Rats.

Authors:  Guohuo Wu; Xiaoyun Sun; Huijun Cheng; Shan Xu; Daxiang Li; Zhongwen Xie
Journal:  Foods       Date:  2022-06-01

Review 5.  CRISPR-Cas systems: role in cellular processes beyond adaptive immunity.

Authors:  Veena Devi; Kusum Harjai; Sanjay Chhibber
Journal:  Folia Microbiol (Praha)       Date:  2022-07-19       Impact factor: 2.629

Review 6.  Rat models of human diseases and related phenotypes: a systematic inventory of the causative genes.

Authors:  Claude Szpirer
Journal:  J Biomed Sci       Date:  2020-08-02       Impact factor: 8.410

7.  Effects of Melanocortin 3 and 4 Receptor Deficiency on Energy Homeostasis in Rats.

Authors:  Panpan You; Handan Hu; Yuting Chen; Yongliang Zhao; Yiqing Yang; Tongtong Wang; Roumei Xing; Yanjiao Shao; Wen Zhang; Dali Li; Huaqing Chen; Mingyao Liu
Journal:  Sci Rep       Date:  2016-10-07       Impact factor: 4.379

8.  Efficient generation of selection-gene-free rat knockout models by homologous recombination in ES cells.

Authors:  He Lan; Shuping Li; Zihang Guo; Hongsheng Men; Yuanyuan Wu; Ning Li; Elizabeth C Bryda; Mario R Capecchi; Sen Wu
Journal:  FEBS Lett       Date:  2016-09-18       Impact factor: 4.124

Review 9.  Genome engineering and disease modeling via programmable nucleases for insulin gene therapy; promises of CRISPR/Cas9 technology.

Authors:  Yunus E Eksi; Ahter D Sanlioglu; Bahar Akkaya; Bilge Esin Ozturk; Salih Sanlioglu
Journal:  World J Stem Cells       Date:  2021-06-26       Impact factor: 5.326

10.  Fischer-344 Tp53-knockout rats exhibit a high rate of bone and brain neoplasia with frequent metastasis.

Authors:  Sarah A Hansen; Marcia L Hart; Susheel Busi; Taybor Parker; Angela Goerndt; Kevin Jones; James M Amos-Landgraf; Elizabeth C Bryda
Journal:  Dis Model Mech       Date:  2016-08-15       Impact factor: 5.758

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.